Medpace downgraded by Robert W. Baird with a new price target

10/23/24 6:30:35 AM ET

Biotechnology: Commercial Physical & Biological Resarch

Health Care

Robert W. Baird downgraded Medpace from Outperform to Neutral and set a new price target of $349.00 from $413.00 previously

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$MEDP

Date	Price Target	Rating	Analyst
6/24/2025	$300.00	Equal Weight	Barclays
4/22/2025		Outperform → Mkt Perform	William Blair
4/14/2025	$328.00	Buy → Hold	TD Cowen
3/24/2025	$330.00	Market Perform	Leerink Partners
10/23/2024	$413.00 → $349.00	Outperform → Neutral	Robert W. Baird
10/14/2024		Buy	Redburn Atlantic
9/27/2024	$420.00 → $350.00	Buy → Neutral	UBS
9/25/2024	$415.00 → $345.00	Buy → Hold	Jefferies